Pancreatic Cancer and Microenvironments: Implications of Anesthesia
Open Access
Abstract
Pancreatic malignancy is a lethal neoplasm, as well as one of the leading causes of cancer-associated mortality, having a 5-year overall survival rate of less than 10%. The average life expectancy of patients with advanced pancreatic cancer does not exceed six months. Although surgical excision is a favorable modality for long-term survival of pancreatic neoplasm, metastasis is initially identified in nearly 80% of the patients by the time of diagnosis, making the development of therapeutic policy for pancreatic cancer extremely daunting. Emerging evidence shows that pancreatic neoplastic cells interact intimately with a complicated microenvironment that can foster drug resistance, metastasis, or relapse in pancreatic cancer. As a result, the necessity of gaining further insight should be focused on the pancreatic microenvironment contributing to cancer progression. Numerous evidence reveals that perioperative factors, including surgical manipulation and anesthetics (e.g., propofol, volatile anesthetics, local anesthetics, epidural anesthesia/analgesia, midazolam), analgesics (e.g., opioids, non-steroidal anti-inflammatory drugs, tramadol), and anesthetic adjuvants (such as ketamine and dexmedetomidine), might alter the tumor microenvironment and cancer progression by affecting perioperative inflammatory or immune responses during cancer surgery. Therefore, the anesthesiologist plays an important role in perioperative management and may affect surgical outcomes. However, the literature on the impact of anesthesia on the pancreatic cancer microenvironment and progression is limited. This review summarizes the current knowledge of the implications of anesthesia in the pancreatic microenvironment and provides future anesthetic strategies for improving pancreatic cancer survival rates.Keywords
This publication has 190 references indexed in Scilit:
- Isoflurane, a Commonly Used Volatile Anesthetic, Enhances Renal Cancer Growth and Malignant Potential via the Hypoxia-inducible Factor Cellular Signaling Pathway In VitroAnesthesiology, 2013
- Effects of sevoflurane and propofol on the inflammatory response and pulmonary function of perioperative patients with one-lung ventilationExperimental and Therapeutic Medicine, 2013
- δ-Opioid Receptor Activation Modified MicroRNA Expression in the Rat Kidney under Prolonged HypoxiaPLOS ONE, 2013
- Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer CellsGastroenterology, 2012
- General Anesthesia Causes Long-term Impairment of Mitochondrial Morphogenesis and Synaptic Transmission in Developing Rat BrainAnesthesiology, 2011
- Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal MarkersMolecular Cancer Research, 2011
- Pain Management in Pancreatic CancerCancers, 2010
- Morphine Suppresses Tumor Angiogenesis through a HIF-1α/p38MAPK PathwayThe American Journal of Pathology, 2010
- Diabetogenic Effect of a Series of Tricyclic Delta Opioid Agonists Structurally Related to CyproheptadineToxicological Sciences, 2010
- Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomasJournal of Surgical Oncology, 2002